VI
Viyash Scientific Ltd (VIYASH)
₹250.90
Mkt cap
₹12,241 Cr
P/E ratio
61.30
P/B
3.77
Div yield
0.00%
ROE
11.00%
ROCE
19.00%
EPS (TTM)
₹4.09
Book value
₹67
52W range
168–294
Sector
Healthcare
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−14.70% from high₹251
₹168+49.31% from low₹294
Current
₹250.90
Prev close
₹251.00
Day
−0.04%
Price performance
1D
−0.04%
1W
−5.16%
1M
−6.83%
3M
+21.12%
6M
+25.81%
1Y
+32.43%
YTD
+19.20%
Financials
FRevenue, profit & margin
P/E ratio
61.3×
VIYASH is 76% above the sector median of 34.9×
VIYASH61.3×
Sector median34.9×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 367 | 333 | 346 | 329 | 361 | 390 | 369 | 774 | 402 | 441 | 850 | 858 | 920 | |
| Expenses | 370 | 341 | 331 | 307 | 329 | 348 | 330 | 674 | 355 | 389 | 677 | 683 | 736 | |
| Operating Profit | -3 | -8 | 15 | 22 | 32 | 42 | 39 | 100 | 46 | 52 | 173 | 176 | 184 | |
| OPM % | -1% | -2% | 4% | 7% | 9% | 11% | 11% | 13% | 12% | 12% | 20% | 20% | 20% | |
| Other Income | -60 | -23 | 10 | 7 | -1 | 3 | 0 | 4 | 1 | 3 | 6 | -27 | 16 | |
| Interest | 11 | 10 | 13 | 13 | 12 | 16 | 14 | 21 | 15 | 14 | 18 | 17 | 15 | |
| Depreciation | 15 | 14 | 15 | 15 | 16 | 16 | 17 | 58 | 16 | 15 | 59 | 59 | 60 | |
| Profit before tax | -89 | -56 | -3 | 1 | 3 | 12 | 8 | 24 | 16 | 26 | 102 | 73 | 125 | |
| Tax % | 4% | -38% | 123% | -617% | 52% | 24% | 20% | -71% | 36% | 31% | 29% | 34% | 47% | |
| Net Profit | -92 | -35 | -7 | 11 | 1 | 9 | 6 | 42 | 10 | 18 | 73 | 49 | 66 | |
| EPS in Rs | -3.75 | -1.40 | -0.34 | 0.33 | -0.04 | 0.26 | 0.10 | 1.78 | 0.37 | 0.57 | 2.18 | 0.88 | 1.19 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202661.31%Promoter
Promoters61.31%0.10
FIIs2.94%0.22
DIIs7.98%0.62
Public27.67%0.30
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,951.50 | 37.73 | 4,68,821 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,273.00 | 73.61 | 1,93,075 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹5,017.80 | 77.52 | 1,69,902 | 0.76% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,438.00 | 30.52 | 1,16,168 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Zydus Lifesci. | ₹1,156.90 | 21.27 | 1,15,401 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,493.00 | 20.04 | 1,13,977 | 0.72% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,543.10 | 52.29 | 1,05,054 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.50% |
| Viyash Scientific | ₹280.45 | 61.29 | 12,241 | 0.00% | 66 | +455.37% | 920 | +129.02% | 19.05% |
| Median: 156 Co. | ₹434.68 | 34.89 | 2,006 | 0.08% | 12 | +22.43% | 177 | +16.46% | 15.19% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2011bse
Concall transcripts58
TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTNov 2025PPTNov 2025TranscriptAug 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024TranscriptOct 2024PPTOct 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 1dDisclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 7 Jul - SEBI issued an administrative warning on SDD maintenance for June 26–Oct. 18, 2024.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 JulShareholder Meeting / Postal Ballot-Scrutinizer"s Report 29 JunClosure of Trading Window 26 Jun